{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T02:23:53Z","timestamp":1775701433802,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ophtha.2025.01.018","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T03:14:09Z","timestamp":1743736449000},"page":"718-730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacologic Agents Used in the Assessment or Correction of Blepharoptosis"],"prefix":"10.1016","volume":"132","author":[{"given":"Seanna R.","family":"Grob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremiah P.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay K.","family":"Aakalu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill A.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lora R.","family":"Dagi Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"McCulley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Reza","family":"Vagefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Wladis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.01.018_bib1","series-title":"The Oxford 2011 levels of evidence","year":"2014"},{"key":"10.1016\/j.ophtha.2025.01.018_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/IOP.0000000000002365","article-title":"Predictability of the phenylephrine test in congenital ptosis: ten years of experience","volume":"39","author":"Akella","year":"2023","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IOP.0000000000000903","article-title":"The phenylephrine test revisited","volume":"34","author":"Barsegian","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib4","first-page":"173","article-title":"Comparison of 2.5% and 10% phenylephrine in the elevation of upper eyelids with ptosis","volume":"21","author":"Glatt","year":"1990","journal-title":"Ophthalmic Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib5","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0002-9394(14)76775-3","article-title":"Palpebral fissure responses to topical adrenergic drugs","volume":"111","author":"Munden","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib6","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3109\/08820538.2015.1045152","article-title":"Quantitative comparison of the effect of 10% phenylephrine instillation and manual elevation in patients with involutional blepharoptosis","volume":"32","author":"Pereira","year":"2017","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/IOP.0000000000000421","article-title":"Dynamic analysis of M\u00fcller's muscle response to phenylephrine","volume":"32","author":"Ramesh","year":"2016","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IOP.0b013e3181462a2e","article-title":"Adrenergic receptors in the ptotic human eyelid: correlation with phenylephrine testing and surgical success in ptosis repair","volume":"23","author":"Skibell","year":"2007","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3341\/kjo.2020.0022","article-title":"Time-dependent response of eyelid height with a single drop of 2.5% phenylephrine in Korean ptotic patients","volume":"34","author":"Shin","year":"2020","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib10","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.18240\/ijo.2022.09.06","article-title":"Clinical value of phenylephrine testing in the upper and lower eyelids of patients with aponeurotic and congenital eyelid ptosis","volume":"15","author":"Gedar Totuk","year":"2022","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/IOP.0b013e31817f526a","article-title":"Use of 0.5% apraclonidine solution in evaluation of blepharoptosis","volume":"24","author":"Yazici","year":"2008","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib12","first-page":"1","article-title":"Response to phenylephrine testing in upper eyelids with ptosis","volume":"21","author":"Grace Lee","year":"2015","journal-title":"Digit J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/DSS.0000000000000967","article-title":"Effect of low-concentration, nonmydriatic selective alpha-adrenergic agonist eyedrops on upper eyelid position","volume":"43","author":"Mendon\u00e7a","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27851","article-title":"Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: a pilot clinical trial","volume":"68","author":"Agha","year":"2023","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ophtha.2025.01.018_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archopht.1988.01060140225029","article-title":"Apraclonidine. A one-week dose-response study","volume":"106","author":"Jampel","year":"1988","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.iop.0000196322.05586.6a","article-title":"Effect of 0.5% apraclonidine on ptosis in Horner syndrome","volume":"22","author":"Garibaldi","year":"2006","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IOP.0000000000000843","article-title":"Upper eyelid response to topical 0.5% apraclonidine","volume":"34","author":"Kirkpatrick","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/DSS.0000000000000386","article-title":"Persistence of upper blepharoptosis after cosmetic botulinum toxin type A","volume":"41","author":"Steinsapir","year":"2015","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jns.2017.03.025","article-title":"Apraclonidine in the treatment of ptosis","volume":"376","author":"Wijemanne","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ophtha.2025.01.018_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/mus.22002","article-title":"Topical naphazoline in the treatment of myasthenic blepharoptosis","volume":"44","author":"Nagane","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ophtha.2025.01.018_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.1993.tb05516.x","article-title":"Topical naphazoline in treatment of myopathic ptosis","volume":"87","author":"Uncini","year":"1993","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ophtha.2025.01.018_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bjps.2023.02.006","article-title":"The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: a randomized controlled trial","volume":"80","author":"Shoji","year":"2023","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jamaophthalmol.2020.3812","article-title":"Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials","volume":"138","author":"Slonim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/asj\/sjab400","article-title":"Changes to eye whiteness and eyelid\/brow position with topical oxymetazoline in aesthetic patients","volume":"42","author":"Ugradar","year":"2022","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.ophtha.2025.01.018_bib26","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.2147\/OPTH.S322326","article-title":"Safety of once-daily oxymetazoline HCl ophthalmic solution, 0.1% in patients with acquired blepharoptosis: results from four randomized, double-masked clinical trials","volume":"15","author":"Wirta","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib27","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.2147\/OPTH.S306155","article-title":"Rapid and sustained eyelid elevation in acquired blepharoptosis with oxymetazoline 0.1%: randomized phase 3 trial results","volume":"15","author":"Bacharach","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib28","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/s41598-024-52990-9","article-title":"A new algorithm for the transconjunctival correction of moderate to severe upper eyelid ptosis in adults","volume":"14","author":"Nowak-Gospodarowicz","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.ophtha.2025.01.018_bib35","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(77)90765-6","article-title":"Eye-drop induced hypertension","volume":"2","author":"Matthews","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2025.01.018_bib48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0002-9394(14)76940-5","article-title":"Hydroxyamphetamine mydriasis in normal subjects","volume":"110","author":"Cremer","year":"1990","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1542\/peds.68.2.231","article-title":"Increased blood pressure following pupillary dilation with 2.5% phenylephrine hydrochloride in preterm infants","volume":"68","author":"Lees","year":"1981","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2025.01.018_bib30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/archopht.1956.00930040184003","article-title":"Hazards of the use of sympathomimetic drugs in ophthalmology","volume":"56","author":"Havener","year":"1956","journal-title":"AMA Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0002-9394(66)90752-5","article-title":"Systemic reactions to topical epinephrine and phenylephrine","volume":"61","author":"Lansche","year":"1966","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000542-197202000-00026","article-title":"Hypertension following 10 per cent phenylephrine ophthalmic","volume":"36","author":"Solosko","year":"1972","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ophtha.2025.01.018_bib33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0002-9394(73)90023-8","article-title":"Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride","volume":"76","author":"Wilensky","year":"1973","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1542\/peds.51.6.1032","article-title":"Systemic hypertension following ocular administration of 10 per cent phenylephrine in the neonate","volume":"51","author":"Borromeo-McGrail","year":"1973","journal-title":"Pediatrics"},{"key":"10.1016\/j.ophtha.2025.01.018_bib36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0002-9394(14)78119-X","article-title":"Hypertensive reactions to phenylephrine eyedrops in patients with sympathetic denervation","volume":"85","author":"Kim","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0002-9394(14)75239-0","article-title":"Possible adverse effects from topical ocular 10% phenylephrine","volume":"85","author":"Fraunfelder","year":"1978","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/0002-9394(79)90361-1","article-title":"Contraindication to the use of ocular phenylephrine in idiopathic orthostatic hypotension","volume":"87","author":"Robertson","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib39","first-page":"1261","article-title":"Hazards of phenylephrine topical medication in persons taking propranolol","volume":"120","author":"Cass","year":"1979","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ophtha.2025.01.018_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3928\/0191-3913-19811101-11","article-title":"Systemic effects of mydriatics in low weight infants","volume":"18","author":"Rosales","year":"1981","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.ophtha.2025.01.018_bib41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0002-9394(82)90545-1","article-title":"Systemic hypertension associated with topical administration of 2.5% phenylephrine hcl","volume":"93","author":"Wellwood","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib42","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0002-9394(85)90371-X","article-title":"Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine","volume":"99","author":"Fraunfelder","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/00006324-197612000-00004","article-title":"Effective degree of mydriasis with phenylephrine and tropicamide","volume":"53","author":"Levine","year":"1976","journal-title":"Am J Optom Physiol Opt"},{"key":"10.1016\/j.ophtha.2025.01.018_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ogla.2022.04.003","article-title":"Acute angle-closure attacks are uncommon in primary angle-closure suspects after pharmacologic mydriasis: the Zhongshan Angle-Closure Prevention Trial","volume":"5","author":"Friedman","year":"2022","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.ophtha.2025.01.018_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/0039-6257(85)90154-7","article-title":"Cocaine\u2019s use in ophthalmology: our 100-year heritage","volume":"29","author":"Altman","year":"1985","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.6.6.637","article-title":"Toxicities of topical ophthalmic anesthetics","volume":"6","author":"McGee","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ophtha.2025.01.018_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0161-6420(93)31672-6","article-title":"Corneal complications associated with the use of crack cocaine","volume":"100","author":"Sachs","year":"1993","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.01.018_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00002341-199903000-00005","article-title":"Distribution of adrenergic receptor subtypes in the retractor muscles of the upper eyelid","volume":"15","author":"Esmaeli-Gutstein","year":"1999","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.ophtha.2025.01.018_bib49","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00055735-199704000-00008","article-title":"The role of alpha-agonists in glaucoma therapy","volume":"8","author":"Robin","year":"1997","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib50","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/archopht.1997.01100150036004","article-title":"Acute and chronic conjunctivitis due to over-the-counter ophthalmic decongestants","volume":"115","author":"Soparkar","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.01.018_bib51","author":"Wiley"},{"key":"10.1016\/j.ophtha.2025.01.018_bib52","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00005537-199605000-00016","article-title":"Effect on the nasal mucosa of long-term treatment with oxymetazoline, benzalkonium chloride, and placebo nasal sprays","volume":"106","author":"Graf","year":"1996","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ophtha.2025.01.018_bib53","first-page":"14","article-title":"Sustained use of xylometazoline nasal spray shortens the decongestive response and induces rebound swelling","volume":"33","author":"Graf","year":"1995","journal-title":"Rhinology"},{"key":"10.1016\/j.ophtha.2025.01.018_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2500\/105065897782537197","article-title":"An evaluation of nasal response following different treatment regimes of oxymetazoline with reference to rebound congestion","volume":"11","author":"Morris","year":"1997","journal-title":"Am J Rhinol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:28:17Z","timestamp":1774344497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0161642025000727"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.01.018","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Agents Used in the Assessment or Correction of Blepharoptosis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}